A recent study revealed that 3 significantly regulated target genes associated with RCT via stimulating the transactivation of LXRα/β, further confirmed as a potent pharmaceutical agent for the treatment of atherosclerosis and hypercholesterolemia, and the prevention of the potential side effect of hepatic steatosis as well (Hien et al., 2017). The gene discussed is NR1H3; the disease is atherosclerosis.